Compare Agnico Eagle Mines Ltd (AEM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Incyte Corporation — how do they compare? Agnico Eagle Mines Ltd trades at $185.38 (market cap $92.01B), while Incyte Corporation trades at $120.51 (market cap $24.54B). The key difference: Agnico Eagle Mines Ltd is far larger — about 3.7× Incyte Corporation's market cap, and Agnico Eagle Mines Ltd pays a 0.99% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AEM | INCY | |
|---|---|---|
Market Cap | $92.01B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $129.93 |
52-Week Low | $130.23 | $81.61 |
Enterprise Value | $88.85B | $20.04B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEM trades at $185.71, up 2.9% over the past day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported robust revenue growth to $11.91 billion in 2025, with a net income margin of 40.44%, and maintains a solid balance sheet with total assets of $29.99 billion. Recent news highlights record free cash flow and a 20-30% gold production growth target through organic expansion.
The stock offers upside to the consensus price target of $219.63, supported by strong profitability and analyst optimism, but faces risks from rising costs and gold price volatility. With 67.74% of analysts rating it a buy, AEM remains a compelling play on gold, though investors should monitor cost pressures and production guidance.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
